+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 14 Actively Recruiting clinical trials

M

Actively Recruiting

Researchers are conducting a Phase 2 clinical trial to create a framework for evaluating the safety and effectiveness of multiple investigational treatments for chronic weight management in adults with obesity or overweight. This master protocol includes intervention-specific appendices ISAs that allow for independent evaluation of different treatments as they become available. Participants may receive various drugs, including LY3305677, LY3841136, tirzepatide, LY3549492, macupatide, eloralintide, or placebo. These treatments are administered either subcutaneously or orally, with each ISA detailing specific intervention plans. The study uses a randomized, double-blind, parallel design to assess these interventions. Participants will be involved in screening and treatment phases, with safety and efficacy monitored throughout. The primary outcome measures the number of participants allocated to each ISA from baseline to week 6. The study is sponsored by Eli Lilly and Company and plans to complete by February 2028, enrolling adults aged 18 to 75 years with obesity or overweight under controlled conditions.

Age: 18Years - 75YearsAll GendersPhase 2
57 locations
E

Actively Recruiting

Researchers are evaluating the efficacy and safety of elecoglipron for weight management in adults living with obesity or overweight. This Phase III global study includes two independent, randomized, double-blind, placebo-controlled pivotal studies. Study 1 involves adults without type 2 diabetes mellitus T2DM, while Study 2 includes adults with T2DM. Participants have obesity or overweight with at least one weight-related comorbidity such as hypertension, prediabetes, dyslipidemia, cardiovascular disease, or obstructive sleep apnea. Participants will be randomly assigned to receive one of two doses of elecoglipron or a placebo once daily as oral tablets. The treatment lasts 72 weeks, and the study is conducted in multiple centers worldwide. The primary measure is the percentage change in body weight from baseline at 72 weeks. Secondary measures include absolute weight loss, achievement of specific weight loss percentages, waist circumference reduction, glycemic control, and systolic blood pressure reduction. Throughout the study, participants will undergo regular assessments including body weight and waist measurements, laboratory tests related to glycemic control, and blood pressure monitoring. Researchers will also track the achievement of normoglycemia and glycemic control in participants with elevated HbA1c levels. Safety and efficacy data will be collected until the study completion in 2029, with participants monitored closely during the 72-week treatment period.

Age: 18Years +All GendersPhase 3
325 locations
L

Actively Recruiting

Healthy Volunteer

Researchers are evaluating the long-term effects of aleniglipron, an oral drug, in adults living with obesity or overweight and type 2 diabetes mellitus T2DM. This randomized, double-blind, placebo-controlled phase 3 study aims to assess the efficacy, safety, and tolerability of multiple doses of aleniglipron for chronic weight management in this population. Participants will be randomly assigned to receive either oral aleniglipron or a placebo once daily. The treatment period lasts for 76 weeks, during which participants will take the assigned medication regularly. The study includes several experimental arms receiving aleniglipron and one placebo arm to compare outcomes. During the study, participants will have assessments at baseline and week 76 to measure changes in body weight, waist circumference, HbA1c levels, blood pressure, triglycerides, and cholesterol. Researchers will track the percentage of participants achieving significant weight loss and HbA1c targets. Safety and tolerability will be monitored throughout the treatment period, with the total participation lasting approximately 76 weeks.

Age: 18Years - 79YearsAll GendersPhase 3
74 locations
P

Actively Recruiting

Researchers are evaluating the safety and effectiveness of eloralintide in adults who are obese or overweight but do not have type 2 diabetes. This Phase 3 clinical trial aims to understand how eloralintide affects body weight and other health measures over time in this population. Participants will be randomly assigned to receive one of four different doses of eloralintide or a placebo, all given by subcutaneous injection. The main phase of the study lasts about 75 weeks, and participants with prediabetes may continue into an extension phase for an additional 2 years to further assess long-term effects. During the study, participants will have regular visits for assessments including body weight, body fat, waist circumference, blood pressure, blood tests, and questionnaires on overall health. Researchers will monitor changes from baseline up to week 64 and longer for some measures, including the time to develop type 2 diabetes. Safety and medication use will also be tracked throughout the study period.

Age: 18Years +All GendersPhase 3
158 locations
E

Actively Recruiting

Researchers are evaluating the efficacy and safety of eloralintide compared with placebo in adults with persistent obesity or overweight. Participants may have type 2 diabetes or not, and all are on stable background therapy with a weekly incretin. This phase 3 randomized, double-blind study aims to understand the effects of eloralintide on body weight and related health outcomes. Participants will be randomly assigned to receive one of four doses of eloralintide or a placebo, all given by subcutaneous injection once weekly. The study treatment period lasts for 64 weeks, during which participants receive their assigned injections. This is a parallel group study, meaning each participant receives only one assigned treatment throughout the trial. Participant involvement spans about 80 weeks, including screening, treatment, and follow-up. Researchers will monitor changes in body weight, waist circumference, blood pressure, blood sugar, insulin, kidney function, inflammation markers, and quality of life using questionnaires. Safety and medication use will also be tracked. Visits and assessments will occur regularly to evaluate the treatment effects and participant well-being.

Age: 18Years +All GendersPhase 3
185 locations
E

Actively Recruiting

Healthy Volunteer

Researchers are evaluating an investigational mRNA seasonal flu vaccine compared to a licensed flu vaccine in adults aged 65 years and older. The study aims to assess the ability of the vaccines to prevent laboratory-confirmed influenza illness, monitor side effects, and measure immune responses during the flu season. This Phase 3 randomized, observer-blind trial is sponsored by GlaxoSmithKline and focuses on flu prevention in older adults. Participants will receive a single injection on Day 1 of either the investigational mRNA seasonal flu vaccine or a licensed, age-appropriate, season-adapted influenza vaccine. The study follows a parallel group design where participants are randomly assigned to one of these two vaccine groups. The follow-up period covers the entire influenza season to assess vaccine efficacy and safety. During the study, participants will be monitored for influenza-like illness confirmed by laboratory tests from Day 15 through the end of the influenza season. Safety assessments include tracking solicited local and systemic side effects from Day 1 to Day 7, unsolicited adverse events up to Day 28, and serious adverse events or special interest adverse events through at least 180 days of follow-up. Blood samples will be collected before dosing and on Day 29 to evaluate immune responses. Participants are followed for safety and efficacy throughout the flu season, with total involvement spanning several months.

Age: 65Years +All GendersPhase 3
163 locations
E

Actively Recruiting

Researchers are evaluating the safety and effectiveness of brenipatide at different dose levels compared to a placebo in adults with uncontrolled moderate to severe asthma. The study aims to understand how brenipatide impacts asthma control and exacerbation rates over time. This phase 2, randomized, double-blind trial involves participants aged 18 to 75 years who have a history of asthma and recent asthma exacerbations. Participants will receive either one of two doses of brenipatide or a placebo, all administered by subcutaneous injection. The treatment period lasts 52 weeks, during which the effects of the study drug on asthma symptoms and lung function will be monitored. The study includes screening, treatment, and follow-up phases, with the overall participation lasting about 65 weeks. During the trial, participants will undergo assessments such as lung function tests, health questionnaires, and monitoring for asthma exacerbations and medication use. Blood samples may be collected to study the drugs behavior in the body and the immune response. Researchers will track safety and treatment effects throughout the study and during follow-up to understand the long-term impact of brenipatide on asthma control.

Age: 18Years - 75YearsAll GendersPhase 2
119 locations
E

Actively Recruiting

The trial investigates the safety and effectiveness of ruxolitinib cream in treating children with nonsegmental vitiligo, a condition causing loss of skin pigment. It is a Phase 3, randomized, double-blind study aimed at evaluating how well this topical treatment works in pediatric participants aged 2 to 11 years with limited body surface affected by vitiligo. Participants are randomly assigned to receive either ruxolitinib 1.5% cream or a matching vehicle cream, both applied twice daily as a thin film to the affected skin areas. The study measures improvements in facial and total body vitiligo using specific scoring indexes over 24 and 52 weeks. Participants must stop other vitiligo treatments during the trial and are monitored for safety throughout. Throughout the study, participants undergo assessments including evaluation of skin pigment improvement using Facial Vitiligo Area Scoring Index F-VASI and Total Body Vitiligo Area Scoring Index T-VASI. Safety is tracked by recording any adverse events up to 30 days after treatment. Pharmacokinetic tests measure drug concentration at multiple time points. The total study duration extends up to nearly four years, with ongoing follow-up to evaluate treatment effects and safety.

Age: 2Years - 11YearsAll GendersPhase 3
98 locations
P

Actively Recruiting

Researchers are evaluating the effects of elecoglipron compared with a placebo in adults with chronic kidney disease CKD, including those with and without type 2 diabetes mellitus T2DM. This Phase III, randomized, double-blind, placebo-controlled study includes participants who are receiving standard care treatments for CKD, including the SGLT2 inhibitor dapagliflozin. The study aims to determine whether elecoglipron can reduce the risk of kidney function decline, end-stage kidney disease, and mortality. Participants will be randomly assigned to receive either elecoglipron tablets or matching placebo tablets once daily. The study is multicenter and involves parallel groups. The treatment period and evaluation are event-driven and may last up to 4.5 years. Both study groups will continue their background therapies for CKD alongside the study medication or placebo. During the study, participants will be monitored regularly to assess kidney function, cardiovascular events, and overall health outcomes, including mortality. Researchers will measure sustained declines in estimated glomerular filtration rate eGFR, occurrence of end-stage kidney disease, cardiovascular death, heart failure hospitalizations, and other related outcomes. The study includes safety monitoring throughout the trial, which is expected to last until October 2030, with participant involvement potentially extending up to 4.5 years.

Age: 18Years +All GendersPhase 3
715 locations
W

Actively Recruiting

This research aims to evaluate the effectiveness and safety of macupatide and eloralintide, alone or combined, in managing weight among adults who are overweight or obese but do not have type 2 diabetes. The study is conducted under a master protocol and seeks to understand how these treatments affect body weight changes over time. Participants are randomly assigned to one of several groups to receive macupatide, eloralintide, their combination, or a placebo. All treatments are given through subcutaneous injections. The study is double-blind, meaning neither participants nor researchers know who receives which treatment. The main treatment period lasts about 36 weeks, with additional assessments extending to around 64 weeks. During the study, participants will be closely monitored through various visits to assess changes in body weight and body mass index. Researchers will measure the percentage change in body weight from the start of the study to week 36 and beyond. Safety and adherence will also be tracked throughout the study, which lasts approximately 64 weeks in total.

Age: 18Years - 75YearsAll GendersPhase 2
40 locations

1-10 of 14

1